Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Joint assessment of health technologies by EU member states expected from 2024

On 17 September 2021, the European Health and Digital Executive Agency (HaDEA) signed the Service Contract for the Provision of Joint Health Technology Assessment Work Supporting the Continuation of EU Cooperation on HTA.

From 2024, the EU member states will prepare joint benefit assessments of health technologies. In order to develop the basic methods for these joint assessments, the EU issued a call for tenders for a competent service provider. The contract has now been awarded to the EUnetHTA21 consortium, which comprises the following 13 organizations from the EUnetHTA: the Spanish Agency of Medicines and Medical Devices (AEMPS, Spain), the Italian Medicines Agency (AIFA, Italy), the Austrian Institute for Health Technology Assessment (AIHTA, Austria), the Federal Joint Committee (G-BA, Germany), the French National Authority for Health (HAS, France), the National Authority of Medicines and Health Products (INFARMED, Portugal), the Institute for Quality and Efficiency in Health Care (IQWiG, Germany), the Belgian Health Care Knowledge Center (KCE, Belgium), the National Centre for Pharmacoeconomics (NCPE, Ireland), the National Institute of Pharmacy and Nutrition (NIPN, Hungary), the Norwegian Medicines Agency (NOMA, Norway), and the Dental and Pharmaceutical Benefits Agency (TLV, Sweden).

The project will start in September 2021 and will run for two years (until September 2023). Over these two years, the EU Commission will fund the further development of the basic methods for implementing the EU HTA regulation with a total of three million euros.

Initially, joint HTA reports will be prepared for all cancer drugs and all advanced therapy medicinal products (e.g., cell therapy and gene therapy). In a second step, drugs for rare diseases will also be jointly assessed, followed by all other drugs and medical devices.

The full details in English can be found here or in German here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.